Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialAleix Prat, Joaquín Gavilá, Xavier González et al.|The Lancet Oncology|2019Cited by 199
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó‐Maristany, Valentina Guarneri, Gaia Griguolo et al.|JNCI Journal of the National Cancer Institute|2022Cited by 25
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancerMaria Vittoria Dieci, Valentina Guarneri, PierFranco Conte et al.|JNCI Journal of the National Cancer Institute|2023Cited by 14
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Esther Sanfeliu, Patricia Villagrasa, Fara Brasó‐Maristany et al.|UNC Libraries|2025Cited by 0